S M van den Berg1, T T P Seijkens1, P J H Kusters1, B Zarzycka2, L Beckers1, M den Toom1, M J J Gijbels3, A Chatzigeorgiou4, C Weber5, M P J de Winther1, T Chavakis4, G A F Nicolaes2, E Lutgens6. 1. Department of Medical Biochemistry, Subdivision of Experimental Vascular Biology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. 2. Department of Biochemistry, University of Maastricht, Maastricht, The Netherlands. 3. 1] Department of Medical Biochemistry, Subdivision of Experimental Vascular Biology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands [2] Department of Pathology, Maastricht University, Maastricht, The Netherlands [3] Department of Molecular Genetics, Maastricht University, Maastricht,The Netherlands. 4. Department of Clinical Pathobiochemistry and Institute for Clinical Chemistry and Laboratory Medicine, Medical Faculty, Technische Universität Dresden, Dresden, Germany. 5. 1] Department of Biochemistry, University of Maastricht, Maastricht, The Netherlands [2] Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian's University, Munich, Germany. 6. 1] Department of Medical Biochemistry, Subdivision of Experimental Vascular Biology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands [2] Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian's University, Munich, Germany.
Abstract
BACKGROUND: Immune processes contribute to the development of obesity and its complications, such as insulin resistance, type 2 diabetes mellitus and cardiovascular disease. Approaches that target the inflammatory response are promising therapeutic strategies for obesity. In this context, we recently demonstrated that the interaction between the costimulatory protein CD40 and its downstream adaptor protein tumor necrosis factor receptor-associated factor 6 (TRAF6) promotes adipose tissue inflammation, insulin resistance and hepatic steatosis in mice in the course of diet-induced obesity (DIO). METHODS: Here we evaluated the effects of a small-molecule inhibitor (SMI) of the CD40-TRAF6 interaction, SMI 6860766, on the development of obesity and its complications in mice that were subjected to DIO. RESULTS: Treatment with SMI 6860766 did not result in differences in weight gain, but improved glucose tolerance. Moreover, SMI 6860766 treatment reduced the amount of CD45(+) leucocytes in the epididymal adipose tissue by 69%. Especially, the number of adipose tissue CD4(+) and CD8(+) T cells, as well as macrophages, was significantly decreased. CONCLUSIONS: Our results indicate that small-molecule-mediated inhibition of the CD40-TRAF6 interaction is a promising therapeutic strategy for the treatment of metabolic complications of obesity by improving glucose tolerance, by reducing the accumulation of immune cells to the adipose tissue and by skewing of the immune response towards a more anti-inflammatory profile.
BACKGROUND: Immune processes contribute to the development of obesity and its complications, such as insulin resistance, type 2 diabetes mellitus and cardiovascular disease. Approaches that target the inflammatory response are promising therapeutic strategies for obesity. In this context, we recently demonstrated that the interaction between the costimulatory protein CD40 and its downstream adaptor protein tumor necrosis factor receptor-associated factor 6 (TRAF6) promotes adipose tissue inflammation, insulin resistance and hepatic steatosis in mice in the course of diet-induced obesity (DIO). METHODS: Here we evaluated the effects of a small-molecule inhibitor (SMI) of the CD40-TRAF6 interaction, SMI 6860766, on the development of obesity and its complications in mice that were subjected to DIO. RESULTS: Treatment with SMI 6860766 did not result in differences in weight gain, but improved glucose tolerance. Moreover, SMI 6860766 treatment reduced the amount of CD45(+) leucocytes in the epididymal adipose tissue by 69%. Especially, the number of adipose tissue CD4(+) and CD8(+) T cells, as well as macrophages, was significantly decreased. CONCLUSIONS: Our results indicate that small-molecule-mediated inhibition of the CD40-TRAF6 interaction is a promising therapeutic strategy for the treatment of metabolic complications of obesity by improving glucose tolerance, by reducing the accumulation of immune cells to the adipose tissue and by skewing of the immune response towards a more anti-inflammatory profile.
Authors: David L Morris; Kelsie E Oatmen; Taleen A Mergian; Kae Won Cho; Jennifer L DelProposto; Kanakadurga Singer; Carmella Evans-Molina; Robert W O'Rourke; Carey N Lumeng Journal: J Leukoc Biol Date: 2015-12-11 Impact factor: 4.962
Authors: Marina Nati; David Haddad; Andreas L Birkenfeld; Christian A Koch; Triantafyllos Chavakis; Antonios Chatzigeorgiou Journal: Rev Endocr Metab Disord Date: 2016-03 Impact factor: 6.514
Authors: Suzanne A B M Aarts; Tom T P Seijkens; Koos J F van Dorst; Christine D Dijkstra; Gijs Kooij; Esther Lutgens Journal: Front Immunol Date: 2017-12-12 Impact factor: 7.561
Authors: Tom T P Seijkens; Claudia M van Tiel; Pascal J H Kusters; Dorothee Atzler; Oliver Soehnlein; Barbara Zarzycka; Suzanne A B M Aarts; Marnix Lameijer; Marion J Gijbels; Linda Beckers; Myrthe den Toom; Bram Slütter; Johan Kuiper; Johan Duchene; Maria Aslani; Remco T A Megens; Cornelis van 't Veer; Gijs Kooij; Roy Schrijver; Marten A Hoeksema; Louis Boon; Francois Fay; Jun Tang; Samantha Baxter; Aldo Jongejan; Perry D Moerland; Gert Vriend; Boris Bleijlevens; Edward A Fisher; Raphael Duivenvoorden; Norbert Gerdes; Menno P J de Winther; Gerry A Nicolaes; Willem J M Mulder; Christian Weber; Esther Lutgens Journal: J Am Coll Cardiol Date: 2018-02-06 Impact factor: 24.094
Authors: Matthijs F Jansen; Maurits R Hollander; Niels van Royen; Anton J Horrevoets; Esther Lutgens Journal: Basic Res Cardiol Date: 2016-05-04 Impact factor: 17.165